PMID- 23317183
OWN - NLM
STAT- MEDLINE
DCOM- 20130702
LR  - 20190606
IS  - 2476-762X (Electronic)
IS  - 1513-7368 (Linking)
VI  - 13
IP  - 11
DP  - 2012
TI  - Immunotherapeutic approach for better management of cancer--role of IL-18.
PG  - 5353-61
AB  - Interleukin-18 (IL-18) is an immune-stimulatory cytokine with antitumor activity 
      in preclinical models. It plays pivotal roles in linking inflammatory immune 
      responses and tumor progression and is a useful candidate in gene therapy of 
      lymphoma or lymphoid leukemia. A phase I study of recombinant human IL-18 
      (rhIL-18) in patients with advanced cancer concluded that rhIL-18 can be safely 
      given in biologically active doses to patients with advanced cancer. Some viruses 
      can induce the secretion of IL-18 for immune evasion. The individual cytokine 
      activity might be potentiated or inhibited by combinations of cytokines. Here we 
      focus on combinational effects of cytokines with IL-18 in cancer progression. 
      IL-18 is an important non-invasive marker suspected of contributing to 
      metastasis. Serum IL-18 may a useful biological marker as independent prognostic 
      factor of survival. In this review we cover roles of IL-18 in immune evasion, 
      metastasis and angiogenesis, applications for chemotherapy and prognostic or 
      diagnostic significance.
FAU - Kuppala, Manohar Babu
AU  - Kuppala MB
AD  - Institute of Genetics and Hospital for Genetic Diseases, Osmania University, 
      Begumpet, Hyderabad, India. hemaprasadm@yahoo.com
FAU - Syed, Sunayana Begum
AU  - Syed SB
FAU - Bandaru, Srinivas
AU  - Bandaru S
FAU - Varre, Sreedevi
AU  - Varre S
FAU - Akka, Jyothy
AU  - Akka J
FAU - Mundulru, Hema Prasad
AU  - Mundulru HP
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - Thailand
TA  - Asian Pac J Cancer Prev
JT  - Asian Pacific journal of cancer prevention : APJCP
JID - 101130625
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Interleukin-18)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/*therapeutic use
MH  - Disease Management
MH  - Humans
MH  - *Immunotherapy
MH  - Interleukin-18/*therapeutic use
MH  - Neoplasms/*drug therapy/immunology
EDAT- 2013/01/16 06:00
MHDA- 2013/07/03 06:00
CRDT- 2013/01/16 06:00
PHST- 2013/01/16 06:00 [entrez]
PHST- 2013/01/16 06:00 [pubmed]
PHST- 2013/07/03 06:00 [medline]
AID - 10.7314/apjcp.2012.13.11.5353 [doi]
PST - ppublish
SO  - Asian Pac J Cancer Prev. 2012;13(11):5353-61. doi: 10.7314/apjcp.2012.13.11.5353.